The company will establish new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong, to scale up its mRNA vaccines and therapeutics
Moderna headquarters in Cambridge, Massachusetts, US. (Credit: Fletcher/Wikipedia)
Moderna, a biotechnology company focused on mRNA therapeutics and vaccines, has unveiled plans to expand its commercial network across Asia with four new subsidiaries.
The company will establish new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong, to scale up the manufacturing and distribution of its mRNA vaccines and therapeutics.
Moderna said that the Asia-Pacific region forms an important part of its business, with established subsidiaries in Japan, South Korea, and Australia.
Last year, the company collaborated with the South Korean government to explore local opportunities for research and manufacturing in the country.
Recently, Moderna signed an agreement in principle with the Australian government to build an advanced mRNA vaccine manufacturing facility in Victoria, Australia.
Moderna CEO Stéphane Bancel said: “2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our presence in Asia.
“After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the Covid-19 pandemic globally.
“With the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our mRNA platform to help solve health challenges, including those with a high burden of disease in the Asia-Pacific region.”
Moderna has a portfolio of prophylactic vaccines, cardiovascular diseases, oncology, and rare diseases using mRNA technology.
The company’s pipeline currently has around 40 development programmes, with 25 programmes currently in clinical trials.
It develops mRNA medicines to prevent and treat diseases with significant unmet needs across infectious, immuno-oncology, rare and ultra-rare, and autoimmune diseases.
The company said that it will update its Covid-19 strategy to address new variants of concern such as Omicron and develop new vaccines and therapeutics.
Moderna currently has a footprint in 12 global markets and its Covid-19 vaccine is approved by the regulators in more than 70 countries.
The company claimed that it has shipped 807 million doses of its Covid-19 vaccine last year, with around 25% of those doses shipped to low- and middle-income markets.